Skip to search formSkip to main contentSkip to account menu

c-Kit Inhibitor PLX9486

Known as: PLX9486 
An orally bioavailable protein tyrosine kinase inhibitor of mutated forms of the tumor-associated antigen mast/stem cell factor receptor c-Kit (SCFR… 
National Institutes of Health

Related topics

Related topics

1 relation
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced…
11509Background: Most metastatic GISTs have primary (10) mut in KIT exons (ex) 9 or 11, which confer sensitivity to imatinib and… 
2015
2015
PLX9486 shows anti-tumor efficacy in a patient-derived gastrointestinal stromal tumor (GIST) xenograft model resistant to standard tyrosine kinase inhibitors (TKI)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)